Your source for the latest medtech news from AdvaMed and our members.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cancer (CRC)…
This week, AdvaMed, the Medtech Association, hosted an Artificial Intelligence (AI) Demonstration Day event on Capitol Hill showcasing AI-enabled medical devices and technologies from leading health care companies. The event…
Today, AdvaMed President and CEO Scott Whitaker released the following statement about U.S. Food and Drug Administration Center for Devices and Radiological Health Director, Dr. Jeff Shuren.
MedTechVets, a leading non-profit organization dedicated to supporting military veterans in transitioning into careers in the medical technology sector, proudly announces Mary McLoughlin will be consulting as Strategic Advisor effective…
If you have media inquiries, please contact:
Cody Uhing, Director, Communications & Media Relations, 202-434-7233
Neuspera Medical, Inc., a neuromodulation company pioneering the Neuspera Implantable Sacral Neuromodulation (SNM) System, announced the closing of its Series D funding round raising $23 million and led by Vertex…
Today, the Centers for Medicare and Medicaid Services (CMS) issued the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System proposed rule for CY25, which includes significant wins…
The Wisconsin Biohealth Tech Hub, led by BioForward Wisconsin, achieves a significant milestone as a Phase 2 recipient of the U.S. Department of Commerce’s Economic Development Administration (EDA) Regional Technology…
In the newest episode of Medtech POV, Steve Mapa, President and Executive Director of MedTechVets, joins host Scott Whitaker to talk about his career in the United States Army and…
Brought to you by AdvaMed, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
The House Ways and Means Committee voted to pass the bipartisan H.R. 1691, Ensuring Patient Access to Critical Breakthrough Products Act, during a markup meeting.